Editing the single "life letters" of the cell in the treatment of T-cell leukemia has a significant effect.

The joint team of University College London and Great Ormond Street Hospital in the UK announced that they have developed a new gene therapy, named BE-CAR7, which has shown significant effectiveness in combating rare aggressive blood cancer - T-cell acute lymphoblastic leukemia. This gene therapy can change the individual "letters of life" - bases within cells, using base editing technology to modify immune cells, clear leukemia cells from the patient's body, and help several previously untreatable patients improve their condition. The relevant clinical trial results were published in the recent issue of the "New England Journal of Medicine".